Frontlight ResearchEarly access
Active, not recruitingPhase 2
Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock
Key facts
- Who runs it
- Inotrem
- Where
- Belgium, Denmark, Finland, France, Ireland, and Spain43 sites in 6 countriesChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 355 people enrolled
- Started
- 13 Nov 2019
- Ended
- 9 May 2023
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- nangibotide low dose
- nangibotide high dose
- placebo
- Record updated
- 11 April 2023
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Provide written informed consent
- Age 18 to 85 years (inclusive)
- Documented or suspected infection: lung, abdominal or urinary tract infection (UTI) in the elderly (≥65 years)
- Organ dysfunction defined as acute change in total SOFA score ≥ 2 points
- Refractory hypotension requiring vasopressors to maintain MAP ≥65mm Hg despite adequate volume resuscitation
- Hyperlactatemia (blood lactate >2 mmol/L or 18 mg/dL)
Who cannot take part
- Previous episode of septic shock requiring vasopressor administration within current hospital stay
- Underlying concurrent immunodepression with anti-CD52 alemtuzumab (Campath) or glucocorticoids >75 mg prednisone daily or equivalent for more than 7 days
- Immunosuppressive therapy related to recent (<6 months) transplantation
- Home oxygen therapy on a regular basis for > 6 h/day
- Participation in another interventional study in the 3 months prior to randomization
- Cancer chemotherapy (<3 months) implying an immunodepression
- Shock of any other cause, e.g. hypotension related to gastrointestinal bleeding
- Ongoing documented or suspected endocarditis, history of prosthetic heart valves
- End-stage neurological disease
- Known HIV infection with low CD4 cell count (<200) for at least 6 months
- Known pregnancy (positive urine or serum pregnancy test)
- Prolonged QT syndrome
- End-stage cirrhosis (Child Pugh Class C)
- Acute Physiology and Chronic Health Evaluation (APACHE II) score <15 or ≥ 34
- Recent cardiopulmonary resuscitation (CPR) (within current hospital stay)
- Body mass index (BMI) ≥ 40 kg/m2or weight ≥ 130 kg
- Moribund patients
- Decision to limit full care taken before obtaining informed consent
This trial has no sites in United States.
It has sites in 6 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a randomized, double-blind, placebo-controlled dose-selection study in which two doses of nangibotide are tested versus placebo.
The 3 groups in the trial
- nangibotide 1Treatment being tested
Treatment with study drug at at dose of 0.3mg/kg/hr
Treatment: nangibotide low dose
- nangibotide 2Treatment being tested
Treatment with study drug at at dose of 1.0mg/kg/hr
Treatment: nangibotide high dose
- PlaceboPlacebo, for comparison
Treatment with a matched placebo infusion
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock. A Randomized, Double-blind, Placebo Controlled Dose Selection Study
- Publications
- Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial.The Lancet. Respiratory medicine, 2023
- Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial.BMJ open, 2021
- Record updated
- 11 April 2023